This news is based on a press release statement from PacBio. The company's products are intended for research purposes only ...

On January 10, 2025, NeoGenomics, Inc. (the “Company”) announced that Christopher Smith, the Company’s Chief Executive ...

FT. MYERS, Fla., January 10, 2025--(BUSINESS WIRE)--NeoGenomics, Inc. ("NeoGenomics" or the "Company") (NASDAQ:NEO), a leading oncology testing services company ...

NeoGenomics has announced a new CEO. The Fort Myers-based cancer testing and research lab, with a national footprint, shared the news Friday, via a press release. Chris Smith, the public company's ...

NeoGenomics (NEO) shares ended the last trading session 9.1% higher at $13.78. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session.

NeoGenomics sees more growth ahead. After announcing a new CEO last week, the local company has provided its financial outlook for this year – and beyond. The Fort Myers-based cancer testing and ...

Pacific Biosciences has moved into its new headquarters at 1305 O'Brien Drive in the Menlo Park Labs office complex in Menlo ...

Bank of America Securities analyst Michael Ryskin maintained a Hold rating on NeoGenomics (NEO – Research Report) yesterday and set a price target of $19.00. Discover outperforming stocks and ...

Ratings for NeoGenomics NEO were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The following table summarizes their recent ratings ...

Needham analyst Michael Matson reiterated a Buy rating on NeoGenomics (NEO – Research Report) today and set a price target of $19.00. Discover outperforming stocks and invest smarter with Top ...